Clinical Trial Update: AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AV-101 (L-4-chlorokynurenine) in Parkinson's disease patients with levodopa-induced dyskinesia; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia Medication-induced
• Parkinson Disease

Drugs mentioned

• AV-101

Snippet

Sponsor: VistaGen Therapeutics, Inc. | Conditions: Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Status: UNKNOWN